221 related articles for article (PubMed ID: 26282839)
1. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
Prayle AP; Jain K; Touw DJ; Koch BC; Knox AJ; Watson A; Smyth AR
J Cyst Fibros; 2016 Jul; 15(4):510-7. PubMed ID: 26282839
[TBL] [Abstract][Full Text] [Related]
2. Urinary Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-1 and Neutrophil Gelatinase-Associated Lipocalin.
McWilliam SJ; Antoine DJ; Jorgensen AL; Smyth RL; Pirmohamed M
Sci Rep; 2018 Mar; 8(1):5094. PubMed ID: 29572451
[TBL] [Abstract][Full Text] [Related]
3. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
[TBL] [Abstract][Full Text] [Related]
4. Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?
van Maarseveen EM; van der Meer R; Neef C; Heijerman HGM; Touw DJ
Ther Drug Monit; 2020 Aug; 42(4):595-599. PubMed ID: 32049889
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Relationship between FEV
Hoff BM; Scheetz MH; Jain M; Cullina JF; Rhodes NJ
Pharmacotherapy; 2020 Jun; 40(6):584-591. PubMed ID: 32259317
[TBL] [Abstract][Full Text] [Related]
6. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
7. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
9. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
10. Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population.
Albright JC; Houck AP; Pettit RS
Pediatr Pulmonol; 2020 Oct; 55(10):2662-2666. PubMed ID: 32568427
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
[TBL] [Abstract][Full Text] [Related]
12. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J
Cochrane Database Syst Rev; 2010 Jan; (1):CD002009. PubMed ID: 20091528
[TBL] [Abstract][Full Text] [Related]
13. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
Hennig S; Norris R; Kirkpatrick CM
Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Brigg Turner R; Elbarbry F; Biondo L
J Chemother; 2016 Aug; 28(4):304-7. PubMed ID: 26430825
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.
Hong LT; Liou TG; Deka R; King JB; Stevens V; Young DC
Chest; 2018 Nov; 154(5):1108-1114. PubMed ID: 29908155
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
Bragonier R; Brown NM
J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
[TBL] [Abstract][Full Text] [Related]
18. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis.
Wood PJ; Ioannides-Demos LL; Li SC; Williams TJ; Hickey B; Spicer WJ; Hooper RE; McLean AJ
Thorax; 1996 Apr; 51(4):369-73. PubMed ID: 8733487
[TBL] [Abstract][Full Text] [Related]
19. A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis.
McWilliam SJ; Rosala-Hallas A; Jones AP; Shaw V; Greenhalf W; Jaki T; Smyth AR; Smyth RL; Pirmohamed M
Sci Rep; 2020 Feb; 10(1):1796. PubMed ID: 32020028
[TBL] [Abstract][Full Text] [Related]
20. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
Aminimanizani A; Beringer PM; Kang J; Tsang L; Jelliffe RW; Shapiro BJ
J Antimicrob Chemother; 2002 Oct; 50(4):553-9. PubMed ID: 12356801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
